Epizyme, Inc.(NASDAQ : EPZM)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||0.51%||64.80||1.0%||$543.24m|
|VRTX||Vertex Pharmaceuticals, Inc.||1.51%||273.73||1.9%||$497.98m|
|REGN||Regeneron Pharmaceuticals, Inc.||1.37%||692.80||2.6%||$444.80m|
|SNSS||Sunesis Pharmaceuticals, Inc.||2.38%||2.15||0.7%||$150.29m|
|EXAS||EXACT Sciences Corp.||7.96%||53.83||17.7%||$134.25m|
|TXG||10X Genomics, Inc.||11.91%||52.99||0.0%||$106.79m|
|BMRN||BioMarin Pharmaceutical, Inc.||2.68%||80.97||4.2%||$95.42m|
|CRSP||CRISPR Therapeutics AG||5.63%||58.34||0.6%||$85.42m|
Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.